GCG and obstructive sleep apnea syndrome: Glucagon‐like peptide‐1 receptor agonist (GLP1RA) and GLP‐1/glucose‐dependent insulinotropic polypeptide (GIP) receptor agonists are promising therapies for OSA, largely through their effects on weight loss and metabolism [6, 20, 21, 22, 23].